Biomarker ID | 1224 |
PMID | 24167554 |
Year | 2013 |
Biomarker | hsa-miR-367; hsa-miR-758; hsa-miR-190 hsa-miR-221; hsa-miR-205; hsa-miR-212; hsa-miR-99b; hsa-miR-214; hsa-miR-203; hsa-miR-127-3p; hsa-miR-130a; hsa-miR-335; hsa-miR-376; hsa-miR-10a; hsa-miR-589; hsa-miR-422a; hsa-miR-10b; hsa-miR-25; hsa-miR-210; hsa-miR-99a; hsa-miR-429; hsa-miR-92a; hsa-miR-100; hsa-miR-222; hsa-miR-484; hsa-miR-125b; hsa-miR-574-3p; hsa-miR-328; hsa-miR-483-5p; hsa-miR-331-3p; hsa-let-7c; hsa-miR-135a; |
Biomarker Basis | Expression Based |
Biomolecule | miRNA |
Source | Tissue |
Subjects | Humans |
Regulation | miR-367, miR-758 and miR-190 were found to be upregulated in PCa; while, rest were Downregulated in PCa |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Prostate Cancer Vs Adjacent Normal |
Type of Biomarker | Diagnostic |
Cohort | 10 PCa patients with Gleason (GS) 6–7 and adjacent normal regions were profiled |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p ≤ 0.046 |
Method Used | Laser Capture Microdissection |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | hsa-miR-367, hsa-miR-758, hsa-miR-190 hsa-miR-221, hsa-miR-205, hsa-miR-212, hsa-miR-99b, hsa-miR-214, hsa-miR-203, hsa-miR-127-3p, hsa-miR-130a, hsa-miR-335, hsa-miR-376, hsa-miR-10a, hsa-miR-589, hsa-miR-422a, hsa-miR-10b, hsa-miR-25, hsa-miR-210, hsa-miR-99a, hsa-miR-429, hsa-miR-92a, hsa-miR-100, hsa-miR-222, hsa-miR-484, hsa-miR-125b, hsa-miR-574-3p, hsa-miR-328, hsa-miR-483-5p, hsa-miR-331-3p, hsa-let-7c, hsa-miR-135a |